These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

599 related items for PubMed ID: 24074764

  • 1. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [Abstract] [Full Text] [Related]

  • 2. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [Abstract] [Full Text] [Related]

  • 3. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 4. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
    Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C.
    Ann Oncol; 2013 Jul; 24(7):1807-1812. PubMed ID: 23576708
    [Abstract] [Full Text] [Related]

  • 5. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [Abstract] [Full Text] [Related]

  • 6. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
    Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.
    Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):122-7. PubMed ID: 25600186
    [Abstract] [Full Text] [Related]

  • 10. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
    Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM.
    Cancer; 2014 Apr 01; 120(7):968-75. PubMed ID: 24382803
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.
    Eur Urol; 2015 Jan 01; 67(1):23-29. PubMed ID: 25018038
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.
    Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN.
    Ann Oncol; 2013 Jul 01; 24(7):1802-1807. PubMed ID: 23585511
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.
    Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.
    Prostate; 2014 Nov 01; 74(15):1560-8. PubMed ID: 25176007
    [Abstract] [Full Text] [Related]

  • 16. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.
    Clin Genitourin Cancer; 2015 Aug 01; 13(4):392-399. PubMed ID: 25708161
    [Abstract] [Full Text] [Related]

  • 17. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
    Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vazquez-Estevez S, González Del Alba A, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, Gonzalez-Billalabeitia E, Attard G.
    Ann Oncol; 2017 Jul 01; 28(7):1508-1516. PubMed ID: 28472366
    [Abstract] [Full Text] [Related]

  • 18. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    Conteduca V, Jayaram A, Romero-Laorden N, Wetterskog D, Salvi S, Gurioli G, Scarpi E, Castro E, Marin-Aguilera M, Lolli C, Schepisi G, Maugeri A, Wingate A, Farolfi A, Casadio V, Medina A, Puente J, Vidal MJM, Morales-Barrera R, Villa-Guzmán JC, Hernando S, Rodriguez-Vida A, González-Del-Alba A, Mellado B, Gonzalez-Billalabeitia E, Olmos D, Attard G, De Giorgi U.
    Eur Urol; 2019 Mar 01; 75(3):368-373. PubMed ID: 30773204
    [Abstract] [Full Text] [Related]

  • 19. Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease.
    Fujimoto N, Minato A, Igawa T, Hiroshige T, Obara W, Fukuda A, Nagata Y, Mizushima Y, Tomisaki I, Harada K.
    Anticancer Res; 2022 Jun 01; 42(6):3041-3047. PubMed ID: 35641266
    [Abstract] [Full Text] [Related]

  • 20. Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.
    Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.
    BMC Res Notes; 2016 Oct 18; 9(1):471. PubMed ID: 27756383
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.